Clinical Trial Detail

NCT ID NCT02811497
Title Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

Her2-receptor negative breast cancer

ovary epithelial cancer

colorectal cancer

Advanced Solid Tumor

Therapies

Azacitidine + Durvalumab

Age Groups: adult senior

No variant requirements are available.